论文部分内容阅读
肝纤维化、肝硬化是多种慢性肝脏疾病的终末期病理表现,目前传统的治疗手段难以从根本上修复肝脏的不可逆变化,肝脏原位移植是治疗各种终末期肝病的有效方法,但是由于供体来源不足、操作复杂、移植后免疫排斥、治疗费用昂贵等问题,限制了临床肝移植的发展。随着细胞移植技术的成熟,肝细胞移植有望从根本上治疗肝脏疾病。干细胞方面的研究为解决肝细胞来源问题带来了希望。间充质干细胞(mesenchymal stem cells,MSCs)是一
Liver fibrosis and cirrhosis are the pathological manifestations of many chronic liver diseases. Currently, the traditional treatment methods are difficult to fundamentally repair the irreversible changes in the liver. Orthotopic liver transplantation is an effective method for the treatment of various end-stage liver diseases. However, Inadequate source of donor, complicated operation, immune rejection after transplantation, expensive treatment and other issues, limiting the development of clinical liver transplantation. With the maturity of cell transplantation technology, liver cell transplantation is expected to fundamentally treat liver disease. Research on stem cells brings hope to solve the problem of liver cell source. Mesenchymal stem cells (MSCs) are one